Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on ...
or multi-branch graft configurations for aortic repair. Trusted for more than 20 years, HEMASHIELD grafts are the most used, most studied vascular products available in the market today.
We value keeping the Device Guide up to date.
We value keeping the Device Guide up to date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback